Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The Androgen Receptor is a Tumor Suppressor in Estrogen Receptor Positive Breast Cancer [T-47D cell line ChIP-seq]

ABSTRACT: The Androgen Receptor is a Tumor Suppressor in Estrogen Receptor Positive Breast Cancer [T-47D cell line ChIP-seq]

PROVIDER: PRJNA533222 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8921300.fastq.gz	Fastqsanger.gz
	SRR8921301.fastq.gz	Fastqsanger.gz
	SRR8921302.fastq.gz	Fastqsanger.gz
	SRR8921303.fastq.gz	Fastqsanger.gz
	SRR8921304.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

The Androgen Receptor is a Tumor Suppressor in Estrogen Receptor Positive Breast Cancer

Project description:The Androgen Receptor is a Tumor Suppressor in Estrogen Receptor Positive Breast Cancer

| PRJNA509775 | ENA

The Androgen Receptor is a Tumor Suppressor in Estrogen Receptor Positive Breast Cancer [ZR-75-1 xenograft RNA-seq]

Project description:The Androgen Receptor is a Tumor Suppressor in Estrogen Receptor Positive Breast Cancer [ZR-75-1 xenograft RNA-seq]

| PRJNA509780 | ENA

The Androgen Receptor is a Tumor Suppressor in Estrogen Receptor Positive Breast Cancer [ZR-75-1 xenograft ChIP-seq]

Project description:The Androgen Receptor is a Tumor Suppressor in Estrogen Receptor Positive Breast Cancer [ZR-75-1 xenograft ChIP-seq]

| PRJNA509781 | ENA

The Androgen Receptor is a Tumor Suppressor in Estrogen Receptor Positive Breast Cancer [PDX model HCI-005 ChIP-seq]

Project description:The Androgen Receptor is a Tumor Suppressor in Estrogen Receptor Positive Breast Cancer [PDX model HCI-005 ChIP-seq]

| PRJNA533223 | ENA

The Androgen Receptor is a Tumor Suppressor in Estrogen Receptor Positive Breast Cancer [PDX model HCI-005 ChIP-seq]

Project description:The role of the androgen receptor (AR) in estrogen receptor alpha (ER) positive breast cancer is controversial, constraining implementation of AR-directed therapies. Using a diverse, clinically relevant panel of cell-line and patient-derived models, we demonstrate that AR activation, not suppression, exerts potent anti-tumor activity in multiple disease contexts, including resistance to standard-of-care ER and CDK4/6 inhibitors. Importantly, AR agonists combined with standard-of-care agents enhanced therapeutic responses. Mechanistically, agonist activation of AR altered the genomic distribution of ER and essential co-activators (p300, SRC-3), resulting in repression of ER-regulated cell cycle genes and up-regulation of AR target genes, including known tumor suppressors. A gene signature of AR activity positively predicted disease survival in multiple clinical ER+ breast cancer cohorts. These findings provide unambiguous evidence that AR has a tumor suppressor role in ER+ breast cancer and support AR agonism as the optimal AR-directed treatment strategy, revealing a rational therapeutic opportunity.

2021-01-18 | GSE129930 | GEO

The Androgen Receptor is a Tumor Suppressor in Estrogen Receptor Positive Breast Cancer [T-47D cell line ChIP-seq]

2021-01-18 | GSE129929 | GEO